News

The biomarkers are especially crucial for patients with lupus nephritis

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

Research findings compare the rotational stability of a monofocal plus toric IOL with traditional toric lenses

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy

Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

A five-step approach to personalise and simplify treatment, leading to higher efficacy

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting